Literature DB >> 20019100

Enhancing fraction in glioma and its relationship to the tumoral vascular microenvironment: A dynamic contrast-enhanced MR imaging study.

S J Mills1, C Soh, J P B O'Connor, C J Rose, G Buonaccorsi, S Cheung, S Zhao, G J M Parker, A Jackson.   

Abstract

BACKGROUND AND
PURPOSE: EnF is a newly described measure of proportional tumor enhancement derived from DCE-MR imaging. The aim of this study was to assess the relationship between EnF and the more established DCE-MR imaging parameters: K(trans), v(e), and v(p).
MATERIALS AND METHODS: Forty-two patients with 43 gliomas (16 grade II, 3 grade III, and 24 grade IV) were studied. Imaging included pre- and postcontrast T1-weighted sequences through the lesion and T1-weighted DCE-MR imaging. Parametric maps of EnF, K(trans), v(e), and v(p) were generated. Voxels were classified as enhancing if the IAUC was positive (EnF(IAUC)(60>0)). A threshold of IAUC > 2.5 mmol.s was used to generate EnF(IAUC)(60>2.5). Both measures of EnF were compared with the DCE-MR imaging parameters (K(trans), v(e), and v(p)).
RESULTS: In grade II gliomas, EnF(IAUC60>0) and EnF(IAUC60>2.5) correlated with v(p) (R(2) = 0.6245, P < .0005; and R(2) = 0.4727, P = .003) but not with K(trans) or v(e). In grade IV tumors, both EnF(IAUC60>0) and EnF(IAUC60>2.5) correlated with K(trans) (R(2) = 0.3501, P = .001; and R(2) = 0.4699, P < .0005) and v(p) (R(2) = 0.1564, P = .01; and R(2) = 0.2429, P = .007), but not with v(e). Multiple regression analysis showed K(trans) as the only independent correlate of both EnF(IAUC60>0) and EnF(IAUC60>2.5) for grade IV tumors.
CONCLUSIONS: This study suggests that in grade II tumors, EnF reflects v(p) and varies due to changes in vascular density. In grade IV gliomas, EnF is affected by K(trans) with secondary associated changes in v(p).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20019100      PMCID: PMC7964223          DOI: 10.3174/ajnr.A1925

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  32 in total

1.  Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected].

Authors:  Yue Cao; Christina I Tsien; Vijaya Nagesh; Larry Junck; Randall Ten Haken; Brian D Ross; Thomas L Chenevert; Theodore S Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-18       Impact factor: 7.038

2.  Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.

Authors:  Meng Law; Sarah Oh; Glyn Johnson; James S Babb; David Zagzag; John Golfinos; Patrick J Kelly
Journal:  Neurosurgery       Date:  2006-06       Impact factor: 4.654

3.  Key factors in the acquisition of contrast kinetic data for oncology.

Authors:  J L Evelhoch
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

4.  Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas?

Authors:  Tufail F Patankar; Hamied A Haroon; Samantha J Mills; Danielle Balériaux; David L Buckley; Geoff J M Parker; Alan Jackson
Journal:  AJNR Am J Neuroradiol       Date:  2005 Nov-Dec       Impact factor: 3.825

5.  Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.

Authors:  Soonmee Cha; Tarik Tihan; Forrest Crawford; Nancy J Fischbein; Susan Chang; Andrew Bollen; Sarah J Nelson; Michael Prados; Mitchel S Berger; William P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2005-02       Impact factor: 3.825

6.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

7.  Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

Authors:  G C Jayson; G J M Parker; S Mullamitha; J W Valle; M Saunders; L Broughton; J Lawrance; B Carrington; C Roberts; B Issa; D L Buckley; S Cheung; K Davies; Y Watson; K Zinkewich-Péotti; L Rolfe; A Jackson
Journal:  J Clin Oncol       Date:  2004-10-04       Impact factor: 44.544

8.  High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion.

Authors:  Meng Law; Jennie E Brodsky; James Babb; Marc Rosenblum; Douglas C Miller; David Zagzag; Michael L Gruber; Glyn Johnson
Journal:  J Magn Reson Imaging       Date:  2007-06       Impact factor: 4.813

9.  Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

Authors:  Saifee A Mullamitha; Nhuan C Ton; Geoff J M Parker; Alan Jackson; Peter J Julyan; Caleb Roberts; Gio A Buonaccorsi; Yvonne Watson; Karen Davies; Sue Cheung; Lynn Hope; Juan W Valle; John A Radford; Jeremy Lawrance; Mark P Saunders; Mihaela C Munteanu; Marian T Nakada; Jeffrey A Nemeth; Hugh M Davis; Qun Jiao; Uma Prabhakar; Zhihui Lang; Robert E Corringham; Robert A Beckman; Gordon C Jayson
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  11 in total

1.  Glioma: Application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading.

Authors:  S C Jung; J A Yeom; J-H Kim; I Ryoo; S C Kim; H Shin; A L Lee; T J Yun; C-K Park; C-H Sohn; S-H Park; S H Choi
Journal:  AJNR Am J Neuroradiol       Date:  2014-01-02       Impact factor: 3.825

2.  Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.

Authors:  Domenico Aquino; Anna Luisa Di Stefano; Alessandro Scotti; Lucia Cuppini; Elena Anghileri; Gaetano Finocchiaro; Maria Grazia Bruzzone; Marica Eoli
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

3.  Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.

Authors:  Jayant Narang; Rajan Jain; Ali Syed Arbab; Tom Mikkelsen; Lisa Scarpace; Mark L Rosenblum; David Hearshen; Abbas Babajani-Feremi
Journal:  Neuro Oncol       Date:  2011-07-29       Impact factor: 12.300

4.  Delayed contrast extravasation MRI: a new paradigm in neuro-oncology.

Authors:  Leor Zach; David Guez; David Last; Dianne Daniels; Yuval Grober; Ouzi Nissim; Chen Hoffmann; Dvora Nass; Alisa Talianski; Roberto Spiegelmann; Galia Tsarfaty; Sharona Salomon; Moshe Hadani; Andrew Kanner; Deborah T Blumenthal; Felix Bukstein; Michal Yalon; Jacob Zauberman; Jonathan Roth; Yigal Shoshan; Evgeniya Fridman; Marc Wygoda; Dror Limon; Tzahala Tzuk; Zvi R Cohen; Yael Mardor
Journal:  Neuro Oncol       Date:  2014-11-30       Impact factor: 12.300

Review 5.  Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.

Authors:  Sarah J Nelson
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

6.  In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach.

Authors:  Dean B Percy; Emeline J Ribot; Yuhua Chen; Catherine McFadden; Carmen Simedrea; Patricia S Steeg; Ann F Chambers; Paula J Foster
Journal:  Invest Radiol       Date:  2011-11       Impact factor: 6.016

7.  Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.

Authors:  Francesca Piludu; Simona Marzi; Andrea Pace; Veronica Villani; Alessandra Fabi; Carmine Maria Carapella; Irene Terrenato; Anna Antenucci; Antonello Vidiri
Journal:  Neuroradiology       Date:  2015-09-12       Impact factor: 2.804

8.  Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.

Authors:  Hyun Seok Choi; Ah Hyun Kim; Sung Soo Ahn; Na-young Shin; Jinna Kim; Seung-Koo Lee
Journal:  Korean J Radiol       Date:  2013-05-02       Impact factor: 3.500

9.  Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas.

Authors:  Julio Arevalo-Perez; Amanuel A Kebede; Kyung K Peck; Eli Diamond; Andrei I Holodny; Marc Rosenblum; Jennifer Rubel; Joshua Gaal; Vaios Hatzoglou
Journal:  J Neuroimaging       Date:  2015-12-26       Impact factor: 2.486

10.  Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis.

Authors:  Vibeke A Larsen; Helle J Simonsen; Ian Law; Henrik B W Larsson; Adam E Hansen
Journal:  Neuroradiology       Date:  2012-12-22       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.